🧬🧬CEO/CSO玉木が第36回バイオメディカル研究会で講演！🧬🧬 ３月４日（火）14:50より、弊社CEO兼CSOの玉木が、「第36回バイオメディカル研究会」（主催：日本バイオインフォマティクス学会、共催：都市活力研究所）にて講演します！ 玉木は「進化分子工学と大規模言語モデルを活用した抗体創薬」と題して、弊社の最先端AI技術と進化分子工学を融合させた抗体の設計・最適化手法についてご紹介します。ぜひご参加ください！ 詳細・参加申込は公式サイトまで： https://lnkd.in/ggACxm3P
Molcure
バイオテクノロジー研究
Kawasaki、Kanagawa590人のフォロワー
We are an AI company focusing on accelerating drug discovery & design.
概要
We combine a deep knowledge of Next Generation Sequencing, Machine Learning and Molecular Biology for accelerated biomolecule discovery.
- ウェブサイト
-
http://molcure.com
Molcureの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 11 - 50名
- 本社
- Kawasaki、Kanagawa
- 種類
- 非上場企業
- 創立
- 2013
- 専門分野
- Antibody、Artificial Intelligence、NGS、Drug Discovery、Biomolecule、Machine Learning、peptide、molecular biology、Directed Evolution
場所
-
プライマリ
道順を表示
7-7, Shinkawasaki, Saiwai
Kawasaki、Kanagawa、212-0032、JP
Molcureの社員
アップデート
-
🧬🧬CEO/CSO Tamaki to Speak at the 36th Biomedical Research Meeting!🧬🧬 On March 4 at 2:50 JST, our CEO/CSO, Dr. Tamaki, will be presenting at the 36th Biomedical Research Meeting, an online event organized by the Japanese Society for Bioinformatics in collaboration with the Urban Innovation Institute. In his talk entitled "Antibody Drug Discovery Leveraging Evolutionary Molecular Engineering and Large Language Models", Dr. Tamaki will showcase how MOLCURE integrates cutting-edge AI technologies with evolutionary molecular engineering to design and optimize high-performance antibodies. Looking forward to connecting with you! The event is conducted in Japanese. Visit the official event page for details and registration: https://lnkd.in/ggACxm3P
-
-
🧬🧬共同研究パートナーからのお知らせ！🧬🧬 私たちの共同研究パートナーであるYumab GmbHが、ケーススタディ・レポートを公開しました！私たちのAI創薬技術とYumabの専門性が今後どのように組み合わさって、新しい創薬の可能性を切り開いていくのか、ご期待ください！ https://lnkd.in/gr5HMw3t
𝐘𝐔𝐌𝐀𝐁’𝐬 𝐕𝐇𝐇 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 Due to their small size and stability, single domain antibodies (e.g. VHH) are of interest in many therapeutic areas. Additionally, they serve as convenient building blocks for the generation of bi- or multispecific antibodies, helping to prevent light-chain mispairing. YUMAB’s VHH discovery platform combines in-vivo immunization of llamas with the power of in-vitro display technologies to identify molecules with high binding affinity, specificity and favorable biochemical properties. Using our YUMAB platform, we discovered VHH specific to CD3 and full-length CD20 by using a novel llama immunization cell line. Check out our latest case study that emerged as part of our collaboration with MOLCURE Inc. 👉 https://lnkd.in/eKbt7vNJ Stay tuned for our next update 😉
-
-
🧬🧬Exciting News from Our Collaboration Partner! 🧬🧬 Our partner Yumab GmbH has just released a thrilling Case Study Report! We are excited to see how our AI-driven drug discovery technology works hand in hand with their expertise. Stay tuned for more updates! https://lnkd.in/gr5HMw3t
𝐘𝐔𝐌𝐀𝐁’𝐬 𝐕𝐇𝐇 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 Due to their small size and stability, single domain antibodies (e.g. VHH) are of interest in many therapeutic areas. Additionally, they serve as convenient building blocks for the generation of bi- or multispecific antibodies, helping to prevent light-chain mispairing. YUMAB’s VHH discovery platform combines in-vivo immunization of llamas with the power of in-vitro display technologies to identify molecules with high binding affinity, specificity and favorable biochemical properties. Using our YUMAB platform, we discovered VHH specific to CD3 and full-length CD20 by using a novel llama immunization cell line. Check out our latest case study that emerged as part of our collaboration with MOLCURE Inc. 👉 https://lnkd.in/eKbt7vNJ Stay tuned for our next update 😉
-
-
🧬🧬CEO/CSO玉木がAIロボット駆動科学シンポジウム 2025に登壇🧬🧬 1/30(木)、弊社CEO/CSOの玉木が「AIロボット駆動科学シンポジウム 2025」（時間：13:00~19:00、場所：品川ザ・グランドホール）にて研究発表を行います！ 16:00からの第3部では、「抗体言語モデルと進化分子工学を融合したAI創薬プラットフォーム」と題して、弊社の最新の研究成果をご紹介します。また、17:00からはポスター発表を予定しており、弊社のAI創薬技術について直接ディスカッションできる貴重な機会です。 このシンポジウムは参加費無料、直前の参加登録も可能です（先着順）。詳細や事前参加登録は、イベント公式サイトをご確認ください。会場で皆様とお会いできるのを楽しみにしています！ 詳細：https://lnkd.in/g3TpXYsy
-
-
🧬🧬CEO/CSO Tamaki to Present at AI Robot-Driven Science Symposium 2025🧬🧬 On January 30, our CEO/CSO, Dr. Tamaki, will be presenting at the AI Robot-Driven Science Symposium 2025 at Shinagawa The Grand Hall (1:00 PM–7:00 PM)! He will take the stage during Part 3, starting at 4:00 PM, to share insights from MOLCURE’s R&D efforts in a talk titled "AI-Driven Drug Discovery Platform Integrating Antibody Language Models and Evolutionary Molecular Engineering". At 5:00 PM, Dr. Tamaki will also participate in a poster presentation, providing a great opportunity to engage in direct discussions about our cutting-edge technologies. The symposium is conducted in Japanese and free to attend, with same-day registration is available on a first-come, first-served basis. For more details and pre-registration, check out the event’s official website. We’d love to see you there! Info: https://lnkd.in/g3TpXYsy
-
-
🧬🧬CEO/CSO玉木が慶應義塾大学先端研究教育連携シンポジウムに登壇！🧬🧬 1月27日（月）、弊社CEO兼CSOの玉木が、慶應義塾大学先端研究教育連携シンポジウム「大学と自治体のパートナーシップ」に登壇します！玉木は、14:30より開催されるパネルトークセッション「スタートアップが飛び出す、慶應義塾×鶴岡市×川崎市のタウンキャンパス」に、パネリストとして出演します。 本シンポジウムは、鶴岡サイエンスパーク内「鶴岡市先端研究産業支援センター」を会場として、オンラインでも参加可能なハイブリッド形式で開催されます。参加費は無料です。シンポジウムの詳細や事前参加申込については、イベント公式サイトをご覧ください。みなさまのご参加をお待ちしています！ 詳細：https://lnkd.in/gaB32_Pq
-
-
🧬🧬CEO/CSO Tamaki to Speak at Keio University’s Advanced Research and Education Symposium🧬🧬 On January 27, our CEO/CSO, Dr. Tamaki, will be speaking as a panelist at Keio University’s Advanced Research and Education Symposium, titled “The Partnership between Universities and Local Governments”! He will join the panel discussion on how startup companies emerge through the partnership between Keio University, Tsuruoka City, and Kawasaki City, starting at 2:30 PM JST. The symposium will be held in a hybrid format, with in-person participation at the Tsuruoka Advanced Research and Industry Support Center in the Tsuruoka Science Park, and online attendance available. Please note that the event will be conducted in Japanese. Participation is free of charge! For more details and to register, visit the event website: https://lnkd.in/gaB32_Pq We hope to see you there!
-
-
🧬🧬共同研究のお知らせ！🧬🧬 MOLCUREは、帝人ファーマ株式会社と共同研究契約を締結しました！本共同研究では、当社のAI創薬プラットフォームを活用し、中枢疾患を対象とした革新的な抗体医薬品の開発を目指します。詳しくは、こちらのプレスリリースをご覧ください: https://lnkd.in/g72DGX9B
-
-
🧬🧬Exciting Joint Research Announcement!🧬🧬 We’re thrilled to announce that MOLCURE Inc. has entered into a joint research agreement with Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. Together, we aim to harness MOLCURE's AI-driven drug discovery platform to develop innovative antibody drugs targeting central nervous system diseases. Learn more by reading the full press release here: https://lnkd.in/gKj-p5ji
-